NEW YORK (360Dx) – Paris-based Sebia said today that it has inked an agreement with Janssen Biotech to develop an in vitro diagnostic test that mitigates potential interference during immunofixation electrophoresis tests that measure a patient’s response to Darzalex (daratumumab), Janssen’s FDA-approved monoclonal antibody used to treat multiple myeloma.

Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.